Management of Superior Vena Cava Syndrome in Critically Ill Cancer Patients

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2017 Aug 25

PMID 28836006

Citations 5

Authors

Sarah Morin

Adeline Grateau

Danielle Reuter

Eric De Kerviler

Constance de Margerie-Mellon

Cedric de Bazelaire

Lara Zafrani

Benoit Schlemmer

Elie Azoulay

Emmanuel Canet

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study is to describe the management and outcome of critically ill cancer patients with Superior Vena Cava Syndrome (SVCS).

Methods: All cancer patients admitted to the medical intensive care unit (ICU) of the Saint-Louis University Hospital for a SVCS between January 2004 and December 2016 were included.

Results: Of the 50 patients included in the study, obstruction of the superior vena cava was partial in two-thirds of the cases and complete in one-third. Pleural effusion was reported in two-thirds of the patients, pulmonary atelectasis in 16 (32%), and pulmonary embolism in five (10%). Computed tomography of the chest showed upper airway compression in 18 (36%) cases, while echocardiography revealed 22 (44%) pericardial effusions. The causes of SVCS were diagnosed one (0-3) day after ICU admission, using interventional radiology procedures in 70% of the cases. Thirty (60%) patients had hematological malignancies, and 20 (40%) had solid tumors. Fifteen (30%) patients required invasive mechanical ventilation, seven (14%) received vasopressors, and renal replacement therapy was implemented in three (6%). ICU, in-hospital, and 6-month mortality rates were 20, 26, and 48%, respectively. The cause of SVCS was the only factor independently associated with day 180 mortality by multivariate analysis. Patients with hematological malignancies had a lower mortality than those with solid tumors (27 versus 80%) (odds ratio 0.12, 95% confidence interval (0.02-0.60), p < 0.01).

Conclusion: Airway obstruction and pleural and pericardial effusions contributed to the unstable condition of cancer patients with SVCS. The vital prognosis of SVCS was mainly related to the underlying diagnosis.

Citing Articles

The anesthetic management and the role of extracorporeal membrane oxygenation for giant mediastinal tumor surgery.

Bertini P, Marabotti A Mediastinum. 2023; 7:2.

PMID: 36926288 PMC: 10011869. DOI: 10.21037/med-22-35.

Principles of medical and oncological management of giant masses of the mediastinum: a narrative review.

Conci N, Grilli G, DallOlio F Mediastinum. 2022; 6:35.

PMID: 36582971 PMC: 9792870. DOI: 10.21037/med-21-54.

Long-term survival of a patient with an inoperable thymic neuroendocrine tumor stage IIIa under sole treatment with Viscum album extract: A CARE compliant clinical case report.

Reynel M, Villegas Y, Werthmann P, Kiene H, Kienle G Medicine (Baltimore). 2020; 99(5):e18990.

PMID: 32000435 PMC: 7004773. DOI: 10.1097/MD.0000000000018990.

Successful stent implantation in a rural area on a patient with superior vena cava syndrome through specialist intervention: a case report.

Watanabe Y, Sakakura K, Kotoku H, Mashimo S, Nakata M, Nagata H J Rural Med. 2019; 14(1):116-119.

PMID: 31191775 PMC: 6545419. DOI: 10.2185/jrm.2990.

Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome.

Ratzon R, Tamir S, Friehmann T, Livneh N, Dudnik E, Rozental A J Thromb Thrombolysis. 2018; 47(1):121-128.

PMID: 30255420 DOI: 10.1007/s11239-018-1747-6.

References

Qanadli S, El Hajjam M, Mignon F, De Kerviler E, Rocha P, Barre O . Subacute and chronic benign superior vena cava obstructions: endovascular treatment with self-expanding metallic stents. AJR Am J Roentgenol. 1999; 173(1):159-64. DOI: 10.2214/ajr.173.1.10397119. View

Azoulay E, Pene F, Darmon M, Lengline E, Benoit D, Soares M . Managing critically Ill hematology patients: Time to think differently. Blood Rev. 2015; 29(6):359-67. DOI: 10.1016/j.blre.2015.04.002. View

Stone M, Bogen S . Evidence-based focused review of management of hyperviscosity syndrome. Blood. 2011; 119(10):2205-8. DOI: 10.1182/blood-2011-04-347690. View

Smayra T, Otal P, Chabbert V, Chemla P, Romero M, Joffre F . Long-term results of endovascular stent placement in the superior caval venous system. Cardiovasc Intervent Radiol. 2002; 24(6):388-94. DOI: 10.1007/s00270-001-0055-1. View

Puxty K, McLoone P, Quasim T, Sloan B, Kinsella J, Morrison D . Risk of Critical Illness Among Patients With Solid Cancers: A Population-Based Observational Study. JAMA Oncol. 2015; 1(8):1078-85. DOI: 10.1001/jamaoncol.2015.2855. View

de Margerie-Mellon C, de Bazelaire C, De Kerviler E . Image-guided biopsy in primary lung cancer: Why, when and how. Diagn Interv Imaging. 2016; 97(10):965-972. DOI: 10.1016/j.diii.2016.06.016. View

Carter B, Erasmus J . Acute Thoracic Findings in Oncologic Patients. J Thorac Imaging. 2015; 30(4):233-46. DOI: 10.1097/RTI.0000000000000148. View

Lemiale V, Mokart D, Resche-Rigon M, Pene F, Mayaux J, Faucher E . Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial. JAMA. 2015; 314(16):1711-9. DOI: 10.1001/jama.2015.12402. View

Khan U, Shanholtz C, McCurdy M . Oncologic mechanical emergencies. Emerg Med Clin North Am. 2014; 32(3):495-508. DOI: 10.1016/j.emc.2014.04.001. View

10.

De Kerviler E, Benet C, Briere J, de Bazelaire C . Image-guided needle biopsy for diagnosis and molecular biology in lymphomas. Best Pract Res Clin Haematol. 2012; 25(1):29-39. DOI: 10.1016/j.beha.2012.01.006. View

11.

Moreau A, Lengline E, Seguin A, Lemiale V, Canet E, Raffoux E . Respiratory events at the earliest phase of acute myeloid leukemia. Leuk Lymphoma. 2014; 55(11):2556-63. DOI: 10.3109/10428194.2014.887709. View

12.

Marcy P, Magne N, Bentolila F, Drouillard J, Bruneton J, Descamps B . Superior vena cava obstruction: is stenting necessary?. Support Care Cancer. 2001; 9(2):103-7. DOI: 10.1007/s005200000173. View

13.

De Kerviler E, de Margerie-Mellon C, Coffin A, Legrand G, Resche-Rigon M, Ploussard G . The feasibility of percutaneous renal cryoablation under local anaesthesia. Cardiovasc Intervent Radiol. 2014; 38(3):672-7. DOI: 10.1007/s00270-014-0995-x. View

14.

Thiery G, Azoulay E, Darmon M, Ciroldi M, de Miranda S, Levy V . Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol. 2005; 23(19):4406-13. DOI: 10.1200/JCO.2005.01.487. View

15.

Wilson L, Detterbeck F, Yahalom J . Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med. 2007; 356(18):1862-9. DOI: 10.1056/NEJMcp067190. View

16.

Zerbib Y, Rabbat A, Fartoukh M, Bige N, Andrejak C, Mayaux J . Urgent Chemotherapy for Life-Threatening Complications Related to Solid Neoplasms. Crit Care Med. 2017; 45(7):e640-e648. DOI: 10.1097/CCM.0000000000002331. View

17.

Maxwell F, de Margerie Mellon C, Bricout M, Cauderlier E, Chapelier M, Albiter M . Diagnostic strategy for the assessment of axillary lymph node status in breast cancer. Diagn Interv Imaging. 2015; 96(10):1089-101. DOI: 10.1016/j.diii.2015.07.007. View

18.

Leung S, Sung T, Wan A, Leung K, Kan W . Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting. Hong Kong Med J. 2015; 21(5):426-34. DOI: 10.12809/hkmj144363. View

19.

Recher C, Coiffier B, Haioun C, Molina T, Ferme C, Casasnovas O . Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011; 378(9806):1858-67. DOI: 10.1016/S0140-6736(11)61040-4. View

20.

Canet E, Zafrani L, Lambert J, Thieblemont C, Galicier L, Schnell D . Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival. PLoS One. 2013; 8(2):e55870. PMC: 3573047. DOI: 10.1371/journal.pone.0055870. View